Posted by Michael Wonder on 17 Nov 2018
FDA approves new drug to treat travelers’ diarrhoea
16 November 2018 - The U.S. FDA today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhoea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
The efficacy of Aemcolo was demonstrated in a randomised, placebo-controlled clinical trial in 264 adults with travelers’ diarrhoea in Guatemala and Mexico. It showed that Aemcolo significantly reduced symptoms of travelers’ diarrhoea compared to the placebo.
The FDA granted Aemcolo a qualified nfectious disease product designation.
